Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

July 29, 2022

Study Completion Date

July 29, 2022

Conditions
Overactive Bladder
Interventions
DRUG

Vibegron

oral administration

Trial Locations (35)

11530

AccuMed Research Associates, Garden City

Urological Surgeons of Long Island, Garden City

33060

Urology Center Of Florida, Pompano Beach

33140

Quantum Clinical Trials, Miami

33351

Precision Clinical Research, Sunrise

33435

Imagine Research of Palm Beach County - Urology, Boynton Beach

33761

Tampa Bay Medical Research, Clearwater

33880

Clinical Research of Central Florida, Winter Haven

35801

Private Practice, Huntsville

44130

Clinical Research Solutions, Middleburg Heights

48703

Beaumont Hospital Royal Oak - Urology Research, Royal Oak

56377

CentraCare Clinic - Adult & Pediatric Urology, Sartell

63901

Poplar Bluff Urology, Poplar Bluff

68114

Adult & Pediatric Urology P.C. - Urology, Omaha

70115

DelRicht Research, New Orleans

71106

Regional Urology, LLC, Shreveport

77030

Advances In Health, Inc., Houston

84107

Wasatch Clinical Research LLC, Salt Lake City

89109

Excel Clinical Research - Internal Medicine, Las Vegas

89144

Private Practice, Las Vegas

90017

American Institute of Research, Los Angeles

90505

Skyline Urology, Torrance

91942

San Diego Clinical Trials, San Diego

92562

Tri Valley Urology Medical Group, Murrieta

95648

Clinical Trials Research, Lincoln

95821

Northern California Research Corp, Sacramento

98166

Seattle Urology Research Center, Burien

02131

Boston Clinical Trials Inc - Urology, Boston

02472

Bay State Clinical Trials, Inc., Watertown

08837

Premier Urology Group, LLC, Edison

07631

New Jersey Urology NJU, Englewood

Unknown

Centrum Medyczne Linden, Krakow

Centrum Medyczne PROMED, Krakow

Medicome Sp. z o.o., Oświęcim

Nzoz Heureka, Piaseczno

All Listed Sponsors
lead

Urovant Sciences GmbH

INDUSTRY

NCT04103450 - Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia | Biotech Hunter | Biotech Hunter